Two Sigma Advisers LP Acquires 121,300 Shares of Progyny, Inc. (NASDAQ:PGNY)

Two Sigma Advisers LP raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 83.8% during the fourth quarter, HoldingsChannel reports. The fund owned 266,100 shares of the company’s stock after purchasing an additional 121,300 shares during the quarter. Two Sigma Advisers LP’s holdings in Progyny were worth $4,590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Voya Investment Management LLC raised its holdings in Progyny by 1.4% during the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock valued at $893,000 after acquiring an additional 701 shares during the period. Signaturefd LLC raised its holdings in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares during the period. KBC Group NV increased its holdings in shares of Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after purchasing an additional 2,140 shares during the period. Finally, F M Investments LLC increased its holdings in shares of Progyny by 13.0% in the fourth quarter. F M Investments LLC now owns 20,420 shares of the company’s stock worth $352,000 after purchasing an additional 2,342 shares during the period. Institutional investors own 94.93% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PGNY. Canaccord Genuity Group decreased their price target on shares of Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, March 31st. Finally, JPMorgan Chase & Co. upped their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Progyny presently has an average rating of “Hold” and a consensus price target of $23.45.

Progyny Stock Down 1.8%

PGNY opened at $20.52 on Monday. The stock has a market cap of $1.76 billion, a PE ratio of 35.38, a P/E/G ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $30.42. The business’s fifty day simple moving average is $22.15 and its 200 day simple moving average is $19.98.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). The firm had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm’s revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. As a group, equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.